Kazuishi Kubota
Discovery Science and Technology Department,
Daiichi Sankyo RD Novare Co., Ltd
Japan
Research Article
Novel Isozyme-Specific Quantitation Method for Alpha-Amylases in Human Plasma Revealed Possible AMY2B Induction by Alpha-Amylase Inhibitor, CS-1036
Author(s): Mayumi Hayashi, Toshiyuki Kosaka, Mitsunori Kato, Tomohiro Honda, Takuo Washio, Atsushi Yamasaki, Kazuishi Kubota and Akira ShinagawaMayumi Hayashi, Toshiyuki Kosaka, Mitsunori Kato, Tomohiro Honda, Takuo Washio, Atsushi Yamasaki, Kazuishi Kubota and Akira Shinagawa
In a clinical trial of an α-amylase inhibitor (CS-1036), which was developed for the treatment of patients with type 2 diabetes, the half-life of plasma CS-1036 concentration was prolonged with the increase of the dose level. The prolonged half-life was assumed to be associated with alternation in the plasma level of any one of the α-amylase isozymes from the treatment. Human α-amylase is classified into 3 isozymes encoded by AMY1A, AMY2A, and AMY2B. Due to high sequence homology between α-amylase isozymes and the low plasma level, it is extremely challenging to quantify individual isozymes. A mass spectrometry-based approach, Multiple Reaction Monitoring (MRM) using the Absolute Quantification (AQUA) strategy, has been applied to quantification of target proteins, and this approach provides high selectivity and specificity. Here we report a novel quantitation .. View More»
DOI: 10.4172/jpb.1000430
